Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.78 |
| ▸ | BRD4 | O60885 | 1/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.78 |
| ▸ | POLB | P06746 | 1/20 | 0.78 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.78 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.65 |
| ▸ | CCR2 | P41597 | 3/20 | 0.58 |
| ▸ | ATM | Q13315 | 1/20 | 0.58 |
| ▸ | HTR2C | P28335 | 2/20 | 0.57 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.57 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.56 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16801703 | 0.88 | KDM4E (0.72) | KDM4EBRD4ALDH1A1POLBCREBBP | |
| SCHEMBL18324984 | 0.87 | KDM4E (0.76) | KDM4EBRD4ALDH1A1POLBCREBBP | |
| SCHEMBL5705098 | 0.87 | KDM4E (1.00) | KDM4EBRD4ALDH1A1POLBCREBBP | |
| SCHEMBL16801846 | 0.86 | KDM4E (0.74) | KDM4EBRD4ALDH1A1POLBCREBBP | |
| SCHEMBL27559063 | 0.86 | KDM4E (0.78) | KDM4EBRD4ALDH1A1POLBCREBBP | |
| SCHEMBL5266659 | 0.85 | CCR2 (0.70) | KDM4EBRD4ALDH1A1POLBCREBBP | |
| SCHEMBL5323484 | 0.85 | KMT2A (0.61) | KDM4EBRD4ALDH1A1POLBCREBBP | |
| SCHEMBL16801496 | 0.85 | KDM4E (0.76) | KDM4EBRD4ALDH1A1POLBCREBBP | |
| SCHEMBL18324709 | 0.85 | KDM4E (0.72) | KDM4EBRD4ALDH1A1POLBCREBBP | |
| SCHEMBL27201572 | 0.85 | HSD11B1 (0.64) | KDM4EBRD4ALDH1A1POLBCREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3717477-A1 | NEW HETEROCYCLIC COMPOUNDS | H. Hoffnabb-La Roche Ag (CH) | 2020-10-07 | — | — | EP | disclosed |
| EP-1691807-A1 | INDOLE DERIVATIVES FOR THE TREATMENT OF BONE DISEASES | Astellas Pharma Inc. (JP) | 2006-08-23 | — | — | EP | disclosed |
| US-20050245540-A1 | New methods | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-11-03 | — | — | US | disclosed |
| US-20050176730-A1 | Amide and urea derivatives as 5-HT reuptake inhibitors and as 5-HT 1B/1D ligands | MERCK PATENT GMBH (DE) | 2005-08-11 | — | — | US | disclosed |
| WO-2005056012-A1 | INDOLE DERIVATIVES FOR THE TREATMENT OF BONE DISEASES | ASTELLAS PHARMA INC. (JP) | 2005-06-23 | — | — | WO | disclosed |
| CN-1191246-C | Indolylpiperidine derivatives as antihistamines and antiallergic agents | ALMIRALL PRODESFARMA SA (ES) | 2005-03-02 | — | — | CN | disclosed |
| US-20030064995-A1 | Amide and urea derivatives as 5-HT reuptake inhibitors and as5-HT1B/1D ligands | MERCK PATENT GMBH (DE) | 2003-04-03 | — | — | US | disclosed |
| US-6509340-B1 | These preparations can be employed as medicaments in human and veterinary medicine. Possible excipients are organic or inorganic substances which are suitable for enteral (e.g. oral) on the central nervous system. | MERCK PATENTGESELLSCHAFT (DE) | 2003-01-21 | — | — | US | disclosed |
| CN-1368969-A | Indolylpiperidine derivatives as antihistaminic and antiallergic agents | ALMIRALL PRODESFARMA SA (ES) | 2002-09-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245540-A1 | New methods | TGFB1, TGFBR1, TGFB2 | KDM4E 3172/4885BRD4 2570/4885ALDH1A1 885/4885 |
| US-20050176730-A1 | Amide and urea derivatives as 5-HT reuptake inhibitors and as 5-HT 1B/1D ligands | HTR1B, HTR1D, HTR1A | KDM4E 2247/4885BRD4 2867/4885ALDH1A1 363/4885 |
| US-20030064995-A1 | Amide and urea derivatives as 5-HT reuptake inhibitors and as5-HT1B/1D ligands | HTR5A, HTR1B, HTR1A | KDM4E 2938/4885BRD4 3943/4885ALDH1A1 1003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.